new tests
PlanAhead™ is a new tool to help a woman make an informed choice about when to have children. It provides the most accurate readily available assessment of her ovarian reserve, or "biological clock". PlanAhead™ uses a proprietary formula to combine measures of several ovary-related hormones and other factors to determine her risk of having a poor egg supply -- and also uses age to indicate her risk of poor egg quality. It takes only a simple blood test and the results are returned in a comprehensive, informative easy-to-read report.
Advanced Sperm Panel Tests Can Improve Take Home Baby Rates
Repromedix’s Advanced Sperm Panel—SDD and SDFA—can help reduce the time, number of hormone injections, and the financial burden associated with repeated ART attempts while increasing chances of pregnancy success. By identifying patients with lower than normal probabilities of successful pregnancies through IUI or IVF, fertility clinicians can avoid delays in helping their patients have a baby.
Read test information.
Repromedix has expanded its ovarian reserve testing capabilities to include AMH (Anti – Mullerian Hormone)
Several recent studies indicate AMH is a better indicator of ovarian reserve and predictor of response to ovarian stimulation. Studies also indicate that AMH levels are more consistent throughout the menstrual cycle and that marked elevations of AMH levels have been associated with PCOS. Repromedix now offers AMH in combination with other ovarian function tests including Inhibin B, AOA (Anti-Ovarian Antibodies), EFFORT (Exogenous FSH Ovarian Reserve), FSH, and Fragile-X. In combination these tests comprise the most advanced and comprehensive selection of ovarian function tests available.
Read the press release
Repromedix Enhances APA Test Panel by Adding Anti-ß2Glycoprotein I Test
With the addition of the Anti-ß2Glycoprotein I Test to the Antiphospholipid Panel, Repromedix sets the standard in helping physicians diagnose patients with complex autoimmune problems. Anti-ß2Glycoprotein I has been significantly linked to early pregnancy loss.
Read the press release
Repromedix Expands Cystic Fibrosis Test Offerings
Repromedix has expanded its genetic testing capabilities with the addition of the CF-48 test for Cystic Fibrosis. This advanced assay simultaneously screens for 42 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations and six variants (polymorphisms.) The gene mutations include the 25 recommended by the American College of Obstetricians & Gynecologists (ACOG) in addition to 15 of the world's most common and North American-prevalent mutations.
Read the press release
Repromedix Adds Antithrombin Activity Test to Thrombophilia Panel
Repromedix has added Antithrombin Activity (AT, previously known as ATIII) to its comprehensive test panel for Thrombophilia. The panel is indicated for conditions including multiple miscarriage, stillbirth, pre-eclampsia, IUFD, and thrombosis.
Download test information
Repromedix Launches Advanced Diagnostic Tests For Male Infertility
Repromedix has launched a panel of two new advanced tests for male infertility that, taken together, provide the clearest indication of a sperm's ability to successfully achieve pregnancy and live birth. One test assesses the level of DNA damage to a patient's sperm while the second measures sperm function post-egg penetration. Taken together these tests go well beyond information provided by traditional sperm testing, such as count and motility.
Read the press release